 Barbara Frederick
Concepts (190)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 11 | 2020 | 543 | 1.330 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2020 | 90 | 0.800 |
Why?
| | Phthalazines | 2 | 2020 | 41 | 0.720 |
Why?
| | Cetuximab | 2 | 2020 | 94 | 0.720 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2020 | 42 | 0.690 |
Why?
| | DNA Repair | 2 | 2020 | 206 | 0.660 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 379 | 0.640 |
Why?
| | Neoplasm Proteins | 2 | 2020 | 422 | 0.620 |
Why?
| | Piperazines | 2 | 2020 | 341 | 0.620 |
Why?
| | Quinazolines | 3 | 2007 | 244 | 0.530 |
Why?
| | Carcinoma, Squamous Cell | 6 | 2014 | 625 | 0.520 |
Why?
| | ErbB Receptors | 5 | 2020 | 605 | 0.460 |
Why?
| | Peptides, Cyclic | 3 | 2020 | 256 | 0.340 |
Why?
| | Mice, Nude | 7 | 2020 | 682 | 0.330 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 2 | 2007 | 107 | 0.310 |
Why?
| | Xenograft Model Antitumor Assays | 8 | 2020 | 812 | 0.300 |
Why?
| | Cell Line, Tumor | 11 | 2020 | 3202 | 0.280 |
Why?
| | Piperidines | 2 | 2007 | 198 | 0.280 |
Why?
| | Mesoderm | 1 | 2007 | 137 | 0.260 |
Why?
| | Smad4 Protein | 2 | 2020 | 38 | 0.260 |
Why?
| | Combined Modality Therapy | 5 | 2020 | 1199 | 0.240 |
Why?
| | Neoplasms | 4 | 2023 | 2449 | 0.230 |
Why?
| | Angiogenesis Inhibitors | 1 | 2006 | 220 | 0.220 |
Why?
| | Neovascularization, Pathologic | 1 | 2006 | 296 | 0.220 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2007 | 756 | 0.190 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2008 | 1049 | 0.190 |
Why?
| | High-Throughput Screening Assays | 1 | 2023 | 138 | 0.180 |
Why?
| | Epithelial Cells | 1 | 2007 | 1063 | 0.180 |
Why?
| | DNA End-Joining Repair | 1 | 2020 | 18 | 0.170 |
Why?
| | Proof of Concept Study | 1 | 2020 | 69 | 0.170 |
Why?
| | Clone Cells | 1 | 2020 | 262 | 0.170 |
Why?
| | DNA, Neoplasm | 1 | 2020 | 158 | 0.170 |
Why?
| | Protein Synthesis Inhibitors | 1 | 2020 | 44 | 0.160 |
Why?
| | Drug Synergism | 1 | 2020 | 370 | 0.160 |
Why?
| | Drosophila melanogaster | 2 | 2012 | 210 | 0.160 |
Why?
| | Prostatic Neoplasms | 3 | 2013 | 1016 | 0.150 |
Why?
| | Cisplatin | 1 | 2020 | 299 | 0.150 |
Why?
| | Lung Neoplasms | 2 | 2008 | 2342 | 0.140 |
Why?
| | Radiation, Ionizing | 3 | 2012 | 76 | 0.140 |
Why?
| | Apoptosis | 4 | 2020 | 2499 | 0.130 |
Why?
| | Mice | 9 | 2020 | 16915 | 0.130 |
Why?
| | DNA Damage | 3 | 2020 | 383 | 0.130 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2020 | 1344 | 0.130 |
Why?
| | Animals | 14 | 2020 | 35309 | 0.120 |
Why?
| | Neoplastic Stem Cells | 1 | 2020 | 379 | 0.120 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2015 | 39 | 0.120 |
Why?
| | Stromal Cells | 1 | 2014 | 105 | 0.110 |
Why?
| | N-Glycosyl Hydrolases | 2 | 2004 | 6 | 0.110 |
Why?
| | Radiation Tolerance | 1 | 2014 | 98 | 0.110 |
Why?
| | Adherens Junctions | 1 | 2013 | 25 | 0.110 |
Why?
| | Plant Proteins | 2 | 2004 | 89 | 0.100 |
Why?
| | Hedgehog Proteins | 1 | 2014 | 187 | 0.100 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2012 | 193 | 0.100 |
Why?
| | Signal Transduction | 6 | 2014 | 4926 | 0.100 |
Why?
| | Sulfones | 1 | 2013 | 108 | 0.100 |
Why?
| | Exosomes | 1 | 2013 | 96 | 0.100 |
Why?
| | Radiation-Protective Agents | 1 | 2012 | 26 | 0.100 |
Why?
| | Glycine | 1 | 2013 | 165 | 0.100 |
Why?
| | Prostate | 1 | 2013 | 179 | 0.100 |
Why?
| | Metalloporphyrins | 1 | 2012 | 101 | 0.100 |
Why?
| | Radiotherapy | 1 | 2012 | 185 | 0.090 |
Why?
| | Disease Models, Animal | 2 | 2020 | 4057 | 0.090 |
Why?
| | Stilbenes | 1 | 2011 | 36 | 0.090 |
Why?
| | Autocrine Communication | 1 | 2011 | 43 | 0.090 |
Why?
| | Maytansine | 1 | 2011 | 16 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1556 | 0.090 |
Why?
| | Receptors, Fibroblast Growth Factor | 1 | 2011 | 65 | 0.090 |
Why?
| | Paclitaxel | 1 | 2012 | 217 | 0.090 |
Why?
| | Neoplasm Invasiveness | 2 | 2013 | 483 | 0.080 |
Why?
| | Prostaglandin D2 | 1 | 2009 | 22 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 2 | 2007 | 84 | 0.080 |
Why?
| | Antioxidants | 1 | 2012 | 558 | 0.080 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2009 | 756 | 0.080 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2009 | 133 | 0.070 |
Why?
| | Up-Regulation | 2 | 2014 | 839 | 0.070 |
Why?
| | Humans | 19 | 2023 | 129271 | 0.070 |
Why?
| | Glutathione | 1 | 2009 | 347 | 0.070 |
Why?
| | Antineoplastic Agents, Phytogenic | 2 | 2011 | 187 | 0.070 |
Why?
| | Receptors, LHRH | 2 | 2004 | 14 | 0.070 |
Why?
| | Cortactin | 1 | 2006 | 7 | 0.070 |
Why?
| | Actin-Related Protein 2-3 Complex | 1 | 2006 | 8 | 0.070 |
Why?
| | Respiratory Mucosa | 1 | 2009 | 307 | 0.070 |
Why?
| | Hypoxia | 1 | 2013 | 1084 | 0.070 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2006 | 56 | 0.070 |
Why?
| | Diagnostic Imaging | 1 | 2008 | 327 | 0.060 |
Why?
| | Cell Division | 1 | 2007 | 796 | 0.060 |
Why?
| | Recombinant Fusion Proteins | 2 | 2008 | 648 | 0.060 |
Why?
| | Protein Biosynthesis | 3 | 2015 | 405 | 0.060 |
Why?
| | Drug Delivery Systems | 2 | 2008 | 333 | 0.060 |
Why?
| | Immunotoxins | 1 | 2004 | 54 | 0.050 |
Why?
| | Cell Cycle | 2 | 2020 | 589 | 0.050 |
Why?
| | Female | 5 | 2020 | 68556 | 0.050 |
Why?
| | Protein Kinase Inhibitors | 1 | 2008 | 890 | 0.050 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2003 | 204 | 0.050 |
Why?
| | Drug Discovery | 1 | 2023 | 131 | 0.050 |
Why?
| | Carcinoma | 1 | 2003 | 215 | 0.050 |
Why?
| | Mutation | 4 | 2013 | 3710 | 0.040 |
Why?
| | Peptide Chain Elongation, Translational | 1 | 2020 | 18 | 0.040 |
Why?
| | HCT116 Cells | 2 | 2011 | 78 | 0.040 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2020 | 132 | 0.040 |
Why?
| | Antineoplastic Agents | 2 | 2008 | 2054 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2020 | 251 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2020 | 208 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2020 | 942 | 0.040 |
Why?
| | Cell Proliferation | 2 | 2020 | 2375 | 0.030 |
Why?
| | Cell Line | 1 | 2023 | 2779 | 0.030 |
Why?
| | Transfection | 2 | 2011 | 915 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2023 | 3080 | 0.030 |
Why?
| | Veratrum Alkaloids | 1 | 2014 | 19 | 0.030 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2014 | 23 | 0.030 |
Why?
| | Cell Survival | 2 | 2011 | 1075 | 0.030 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2014 | 37 | 0.030 |
Why?
| | Ribosome Inactivating Proteins, Type 1 | 2 | 2004 | 3 | 0.030 |
Why?
| | Annexin A2 | 1 | 2013 | 10 | 0.030 |
Why?
| | Tetraspanins | 1 | 2013 | 18 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 958 | 0.030 |
Why?
| | HeLa Cells | 1 | 2015 | 611 | 0.030 |
Why?
| | Metalloproteases | 1 | 2013 | 44 | 0.030 |
Why?
| | CHO Cells | 2 | 2004 | 154 | 0.030 |
Why?
| | Cricetinae | 2 | 2004 | 278 | 0.030 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 81 | 0.030 |
Why?
| | Models, Biological | 2 | 2012 | 1722 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2013 | 223 | 0.030 |
Why?
| | Heat-Shock Proteins | 1 | 2013 | 136 | 0.030 |
Why?
| | Blotting, Western | 2 | 2007 | 1204 | 0.030 |
Why?
| | Papillomaviridae | 1 | 2013 | 114 | 0.030 |
Why?
| | Cell Hypoxia | 1 | 2013 | 235 | 0.030 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2014 | 201 | 0.020 |
Why?
| | Penis | 1 | 2012 | 35 | 0.020 |
Why?
| | Erectile Dysfunction | 1 | 2012 | 39 | 0.020 |
Why?
| | Testis | 1 | 2012 | 144 | 0.020 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 396 | 0.020 |
Why?
| | Comet Assay | 1 | 2011 | 17 | 0.020 |
Why?
| | Prognosis | 1 | 2020 | 3773 | 0.020 |
Why?
| | Glioma | 1 | 2015 | 347 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2013 | 360 | 0.020 |
Why?
| | BRCA1 Protein | 1 | 2011 | 65 | 0.020 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2011 | 82 | 0.020 |
Why?
| | Immunoblotting | 1 | 2011 | 305 | 0.020 |
Why?
| | Cells, Cultured | 2 | 2011 | 4077 | 0.020 |
Why?
| | Spindle Apparatus | 1 | 2011 | 94 | 0.020 |
Why?
| | Larva | 1 | 2011 | 214 | 0.020 |
Why?
| | Mitosis | 1 | 2011 | 180 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 635 | 0.020 |
Why?
| | Papillomavirus Infections | 1 | 2013 | 297 | 0.020 |
Why?
| | tert-Butylhydroperoxide | 1 | 2009 | 10 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2013 | 584 | 0.020 |
Why?
| | Cell Death | 1 | 2011 | 354 | 0.020 |
Why?
| | Cytoprotection | 1 | 2009 | 56 | 0.020 |
Why?
| | Proteome | 1 | 2013 | 438 | 0.020 |
Why?
| | Cell Movement | 1 | 2013 | 944 | 0.020 |
Why?
| | Src Homology 2 Domain-Containing, Transforming Protein 1 | 1 | 2008 | 12 | 0.020 |
Why?
| | Shc Signaling Adaptor Proteins | 1 | 2008 | 12 | 0.020 |
Why?
| | GRB2 Adaptor Protein | 1 | 2008 | 13 | 0.020 |
Why?
| | Biological Products | 1 | 2012 | 200 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2009 | 368 | 0.020 |
Why?
| | Luciferases | 1 | 2008 | 147 | 0.020 |
Why?
| | Benzimidazoles | 1 | 2009 | 162 | 0.020 |
Why?
| | Survival Analysis | 1 | 2011 | 1269 | 0.020 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2011 | 432 | 0.020 |
Why?
| | Skin | 1 | 2012 | 726 | 0.020 |
Why?
| | Genes, Reporter | 1 | 2008 | 265 | 0.020 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2011 | 509 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2009 | 580 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2012 | 2396 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2011 | 1691 | 0.020 |
Why?
| | Brain Neoplasms | 1 | 2015 | 1143 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2007 | 256 | 0.020 |
Why?
| | Transcription Factors | 1 | 2014 | 1647 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2008 | 812 | 0.020 |
Why?
| | Histones | 1 | 2011 | 588 | 0.020 |
Why?
| | Gene Amplification | 1 | 2006 | 105 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2008 | 399 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2006 | 313 | 0.020 |
Why?
| | Chromosome Mapping | 1 | 2006 | 504 | 0.010 |
Why?
| | Colony-Forming Units Assay | 1 | 2004 | 90 | 0.010 |
Why?
| | Male | 4 | 2013 | 63517 | 0.010 |
Why?
| | Actins | 1 | 2006 | 411 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2007 | 1247 | 0.010 |
Why?
| | Tumor Stem Cell Assay | 1 | 2003 | 32 | 0.010 |
Why?
| | Rats | 1 | 2012 | 5482 | 0.010 |
Why?
| | Pituitary Gland | 1 | 2004 | 148 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2009 | 1266 | 0.010 |
Why?
| | Drug Combinations | 1 | 2003 | 330 | 0.010 |
Why?
| | Cattle | 1 | 2004 | 977 | 0.010 |
Why?
| | Cell Membrane | 1 | 2004 | 733 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2003 | 867 | 0.010 |
Why?
| | Protein Binding | 1 | 2004 | 2120 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2003 | 2703 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2008 | 10202 | 0.010 |
Why?
|
|
Frederick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|